The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain
Open accessAbstract
BACKGROUND: Protein tyrosine kinases are important regulators of cellular homeostasis with tightly controlled catalytic activity. Mutations in kinase-encoding genes can relieve the autoinhibitory constraints on kinase activity, can promote malignant transformation, and appear to be a major determinant of response to kinase inhibitor therapy. Missense mutations in the EGFR kinase domain, for example, have recently been identified in patients who showed clinical responses to EGFR kinase inhibitor therapy. METHODS AND FINDINGS: Encouraged by the promising clinical activity of epidermal growth factor receptor (EGFR) kinase inhibitors in treating glioblastoma in humans, we have sequenced the complete EGFR coding sequence in glioma tumor samples and cell lines. We identified novel missense mutations in the extracellular domain of EGFR in 13.6% (18/132) of glioblastomas and 12.5% (1/8) of glioblastoma cell lines. These EGFR mutations were associated with increased EGFR gene dosage and conferred anchorage-independent growth and tumorigenicity to NIH-3T3 cells. Cells transformed by expression of these EGFR mutants were sensitive to small-molecule EGFR kinase inhibitors. CONCLUSIONS: Our results suggest extracellular missense mutations as a novel mechanism for oncogenic EGFR activation and may help identify patients who can benefit from EGFR kinase inhibitors for treatment of glioblastoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“Encouraged by the recent success in identifying oncogenic kinase mutations through resequencing of kinase-encoding genes [17–19], we sequenced the entire coding sequence of EGFR in 143 human glioma samples and eight glioblastoma cell lines.”
BackgroundEGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationPao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection.
Li, C., & Wong, W. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.31 · Cited by 3,133
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Self-citationOverriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
Self-citationThe WHO classification of tumors of the nervous system
Kleihues, P., Louis, D. N., Scheithauer, B. W., Rorke, L. B., Reifenberger, G., Burger, P. C., & Cavenee, W. K. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.3.215 · Cited by 1,547
Libermann, T. A., Nusbaum, H. R., Razon, N., Kris, R., Lax, I., Soreq, H., Whittle, N., Waterfield, M. D., Ullrich, A., & Schlessinger, J. (1985) · Nature · doi:10.1038/313144a0 · Cited by 1,503
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
Self-citationStructural basis for inhibition of the epidermal growth factor receptor by cetuximab
Li, S., Schmitz, K. R., Jeffrey, P. D., Wiltzius, J. J. W., Kussie, P., & Ferguson, K. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.003 · Cited by 1,118
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.
Nishikawa, R., Ji, X. D., Harmon, R. C., Lazar, C. S., Gill, G. N., Cavenee, W. K., & Huang, H. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.16.7727 · Cited by 936
Structural alterations of the epidermal growth factor receptor gene in human gliomas.
Wong, A. J., Ruppert, J. M., Bigner, S. H., Grzeschik, C. H., Humphrey, P. A., Bigner, D. S., & Vogelstein, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.2965 · Cited by 853
Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.
Frederick, L. A., Wang, X. Y., Eley, G. D., & James, C. D. (2000) · PubMed · Cited by 740
Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
Baselga, J., & Arteaga, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.890 · Cited by 725
Palacios, R., & Steinmetz, M. (1985) · Cell · doi:10.1016/s0092-8674(85)80053-2 · Cited by 688
Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants
Greulich, H., Chen, T.-H., Feng, W., Jänne, P. A., Alvarez, J. V., Zappaterra, M., Bulmer, S. E., Frank, D. A., Hahn, W. C., Sellers, W. R., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020313 · Cited by 677 · cited 1×
“EGFR Expression Constructs Retroviral EGFR expression constructs containing puromycin (pBabe-puro-EGFR) [13] or neomycin-resistance genes (pLXSN-neo-EGFR) [14] were used for site-directed mutagenesis using the Quick-Change Mutagenesis XL kit (Stratagene, http://www.”
MethodSelf-citationDi Fiore, P. P., Pierce, J. H., Fleming, T. P., Hazan, R., Ullrich, A., King, C. R., Schlessinger, J., & Aaronson, S. A. (1987) · Cell · doi:10.1016/0092-8674(87)90592-7 · Cited by 640
Ekstrand, A. J., Sugawa, N., James, C. D., & Collins, V. P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4309 · Cited by 602
Daley, G. Q., & Baltimore, D. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.23.9312 · Cited by 572
Analysis of array CGH data: from signal ratio to gain and loss of DNA regions
Hupé, P., Stransky, N., Thiery, J.-P., Radvanyi, F., & Barillot, E. (2004) · Bioinformatics · doi:10.1093/bioinformatics/bth418 · Cited by 521
Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers
Bardelli, A., Parsons, D. W., Silliman, N., Ptak, J., Szabo, S., Saha, S., Markowitz, S., Willson, J. K. V., Parmigiani, G., Kinzler, K. W., et al. (2003) · Science · doi:10.1126/science.1082596 · Cited by 484
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
Haas-Kogan, D. A., Prados, M. D., Tihan, T., Eberhard, D. A., Jelluma, N., Arvold, N. D., Baumber, R., Lamborn, K. R., Kapadia, A., Malec, M., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji161 · Cited by 465
Epidermal-Growth-Factor-Dependent Transformation by a Human EGF Receptor Proto-Oncogene
Velu, T. J., Beguinot, L., Vass, W. C., Willingham, M. C., Merlino, G. T., Pastan, I., & Lowy, D. R. (1987) · Science · doi:10.1126/science.3500513 · Cited by 433
High level multiplex genotyping by MALDI-TOF mass spectrometry
Ross, P., Hall, L., Smirnov, I., & Haff, L. (1998) · Nature Biotechnology · doi:10.1038/4328 · Cited by 408
The Cellular Response to Neuregulins Is Governed by Complex Interactions of the erbB Receptor Family
Riese, D. J., van Raaij, T. M., Plowman, G. D., Andrews, G. C., & Stern, D. F. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.10.5770 · Cited by 368
Trafficking of the ErbB receptors and its influence on signaling
Wiley, H. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(03)00002-8 · Cited by 348
Somatic Mutations of EGFR in Colorectal Cancers and Glioblastomas
Barber, T. D., Vogelstein, B., Kinzler, K. W., & Velculescu, V. E. (2004) · New England Journal of Medicine · doi:10.1056/nejm200412303512724 · Cited by 315
Recent Advances in the Treatment of Malignant Astrocytoma
Reardon, D. A., Rich, J. N., Friedman, H. S., & Bigner, D. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5302 · Cited by 307
Sonoda, Y., Ozawa, T., Hirose, Y., Aldape, K. D., McMahon, M., Berger, M. S., & Pieper, R. O. (2001) · PubMed · Cited by 298
Self-citationKobayashi, S., Ji, H., Yuza, Y., Meyerson, M., Wong, K.-K., Tenen, D. G., & Halmos, B. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1346 · Cited by 272
Self-citationGrowney, J. D., Clark, J. J., Adelsperger, J., Stone, R., Fabbro, D., Griffin, J. D., & Gilliland, D. G. (2005) · Blood · doi:10.1182/blood-2004-12-4617 · Cited by 249
Signal Transduction Through the EGF Receptor Transfected in IL-3-Dependent Hematopoietic Cells
Pierce, J. H., Ruggiero, M., Fleming, T. P., Di Fiore, P. P., Greenberger, J. S., Varticovski, L., Schlessinger, J., Rovera, G., & Aaronson, S. A. (1988) · Science · doi:10.1126/science.3257584 · Cited by 226
Cools, J., Stover, E. H., Boulton, C. L., Gotlib, J., Legare, R. D., Amaral, S. M., Curley, D. P., Duclos, N., Rowan, R., Kutok, J. L., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00108-9 · Cited by 216
Yamazaki, H., Fukui, Y., Ueyama, Y., Tamaoki, N., Kawamoto, T., Taniguchi, S., & Shibuya, M. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.4.1816 · Cited by 212
Jiang, J., Greulich, H., Jänne, P. A., Sellers, W. R., Meyerson, M., & Griffin, J. D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1829 · Cited by 186
Self-citationSequence survey of receptor tyrosine kinases reveals mutations in glioblastomas
Rand, V., Huang, J., Stockwell, T., Ferriera, S., Buzko, O., Levy, S., Busam, D., Li, K., Edwards, J. B., Eberhart, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507200102 · Cited by 159
Self-citationYang, S., Qu, S., Perez-Tores, M., Sawai, A., Rosen, N. X., Solit, D. B., & Arteaga, C. L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1042 · Cited by 89
EGFR tyrosine kinase domain mutations in human gliomas
Marie, Y., Carpentier, A. F., Omuro, A. M. P., Sanson, M., Thillet, J., Hoang‐Xuan, K., & Delattre, J. (2005) · Neurology · doi:10.1212/01.wnl.0000158654.07080.b0 · Cited by 79
EGFRMutations and Sensitivity to Gefitinib
Rossi, G., Marchioni, A., & Longo, L. (2004) · New England Journal of Medicine · doi:10.1056/nejm200409163511221 · Cited by 72
Transfer of functional EGF receptors to an IL3‐dependent cell line
Collins, M. K., Downward, J., Miyajima, A., Maruyama, K., Arai, K., & Mulligan, R. C. (1988) · Journal of Cellular Physiology · doi:10.1002/jcp.1041370212 · Cited by 50
Arjona, D., Bello, M. J., Alonso, M. E., Amiñoso, C., Isla, A., de Campos, J. M., Sarasa, J. L., Gutierrez, M., Villalobo, A., & REY, J. A. (2005) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2005.00653.x · Cited by 48
Biochemical characterization of mutant EGF receptors expressed in the hemopoietic cell line BaF/3
Walker, F., Hibbs, M. L., Zhang, H., Góñez, L. J., & Burgess, A. W. (1998) · Growth Factors · doi:10.3109/08977199809017491 · Cited by 35
Calculated resistance in cancer
Sawyers, C. L. (2005) · Nature Medicine · doi:10.1038/nm0805-824 · Cited by 25
Self-citation
Cited by
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
“Spellman(28), Elizabeth Purdom(29), Lakshmi R.”
InfluentialWen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316
“…results, coupled with the recent identification of EGFR-activating ectodomain mutations in ∼ 14% of GBMs that convey sensitivity toward erlotinib (Lee et al. 2006), are beginning to detail tumor molecular profiles and therapeutic regimens that will best benefit patients with EGF receptor and…”
BackgroundEpidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
Metadata
- Authors
- Lee, J. C., Vivanco, I., Beroukhim, R., Huang, J. H. Y., Feng, W. L., DeBiasi, R. M., Yoshimoto, K., King, J. C., Nghiemphu, P., Yuza, Y., Xu, Q., Greulich, H., Thomas, R. K., Paez, J. G., Peck, T. C., Linhart, D. J., Glatt, K. A., Getz, G., Onofrio, R., Ziaugra, L., Levine, R. L., Gabriel, S., Kawaguchi, T., O'Neill, K., Khan, H., Liau, L. M., Nelson, S. F., Rao, P. N., Mischel, P., Pieper, R. O., Cloughesy, T., Leahy, D. J., Sellers, W. R., Sawyers, C. L., Meyerson, M., & Mellinghoff, I. K.
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2006-12-19
- Volume
- 3
- Issue
- 12
- Pages
- e485
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2117521607
- Cited by
- 367
- References
- 46
- FWCI
- 7.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.